
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression
Ella Day | July 25, 2025 | News story | Research and Development | Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of allopregnanolone, for the treatment of major depressive disorder (MDD), with or without anxious distress. GlyphAllo is designed using the company’s Glyph platform to overcome bioavailability limitations of allopregnanolone, a molecule known for its rapid antidepressant and anti-anxiety effects.
The BUOY-1 trial is a global study that aims to enrol approximately 360 adults with MDD. Patients will receive either GlyphAllo or placebo daily for six weeks, and will measure change in severity of depression as measured by the HAM-D-17 scale.
“This is an important step on our journey to deliver new treatments for patients living with depression, anxiety and other neuropsychiatric conditions,” said Daphne Zohar, CEO of Seaport Therapeutics.
Seaport’s prior phase 1 and 2a data showed that GlyphAllo achieved high brain exposure and reduced stress hormone levels in a validated anxiety model. In healthy volunteers, the compound demonstrated dose-dependent engagement with its neurological target and was well tolerated.
Built on technology licensed from Monash University, Australia, the Glyph platform allows oral delivery through the lymphatic system, improving absorption while avoiding first-pass liver metabolism.
Ella Day
25/7/25

This article featured in: August 2025 – The Pharmafile Brief
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

FDA approves first new fibromyalgia therapy in over 15 years
The US Food and Drug Administration (FDA) has approved Tonix Pharmaceutical’s Tonmya (cyclobenzaprine hydrochloric acid) …






